JP2021113201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021113201A5 JP2021113201A5 JP2021066291A JP2021066291A JP2021113201A5 JP 2021113201 A5 JP2021113201 A5 JP 2021113201A5 JP 2021066291 A JP2021066291 A JP 2021066291A JP 2021066291 A JP2021066291 A JP 2021066291A JP 2021113201 A5 JP2021113201 A5 JP 2021113201A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eye
- multikinase
- multikinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 229940124303 multikinase inhibitor Drugs 0.000 claims 9
- -1 ambatinib Chemical compound 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 239000007943 implant Substances 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 229960003005 axitinib Drugs 0.000 claims 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 2
- 229960004378 nintedanib Drugs 0.000 claims 2
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical group O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 201000004768 pinguecula Diseases 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005461 Canertinib Substances 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 229950002205 dacomitinib Drugs 0.000 claims 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229950008692 foretinib Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229960001131 ponatinib Drugs 0.000 claims 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 1
- 206010037147 pseudopterygium Diseases 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023024878A JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
| JP2024035547A JP7838007B2 (ja) | 2015-06-06 | 2024-03-08 | 翼状片を治療するための組成物及び方法 |
| JP2025044397A JP7774170B2 (ja) | 2015-06-06 | 2025-03-19 | 翼状片を治療するための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172063P | 2015-06-06 | 2015-06-06 | |
| US62/172,063 | 2015-06-06 | ||
| US201562186660P | 2015-06-30 | 2015-06-30 | |
| US62/186,660 | 2015-06-30 | ||
| JP2018515193A JP6868014B2 (ja) | 2015-06-06 | 2016-06-03 | 翼状片を治療するための組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515193A Division JP6868014B2 (ja) | 2015-06-06 | 2016-06-03 | 翼状片を治療するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023024878A Division JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021113201A JP2021113201A (ja) | 2021-08-05 |
| JP2021113201A5 true JP2021113201A5 (enExample) | 2022-02-09 |
| JP7234283B2 JP7234283B2 (ja) | 2023-03-07 |
Family
ID=57504837
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515193A Active JP6868014B2 (ja) | 2015-06-06 | 2016-06-03 | 翼状片を治療するための組成物及び方法 |
| JP2021066291A Active JP7234283B2 (ja) | 2015-06-06 | 2021-04-09 | 翼状片を治療するための組成物及び方法 |
| JP2023024878A Active JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
| JP2024035547A Active JP7838007B2 (ja) | 2015-06-06 | 2024-03-08 | 翼状片を治療するための組成物及び方法 |
| JP2025044397A Active JP7774170B2 (ja) | 2015-06-06 | 2025-03-19 | 翼状片を治療するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515193A Active JP6868014B2 (ja) | 2015-06-06 | 2016-06-03 | 翼状片を治療するための組成物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023024878A Active JP7571171B2 (ja) | 2015-06-06 | 2023-02-21 | 翼状片を治療するための組成物及び方法 |
| JP2024035547A Active JP7838007B2 (ja) | 2015-06-06 | 2024-03-08 | 翼状片を治療するための組成物及び方法 |
| JP2025044397A Active JP7774170B2 (ja) | 2015-06-06 | 2025-03-19 | 翼状片を治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US9980901B2 (enExample) |
| EP (2) | EP3302379B1 (enExample) |
| JP (5) | JP6868014B2 (enExample) |
| KR (5) | KR20260025887A (enExample) |
| CN (2) | CN108135737B (enExample) |
| AU (3) | AU2016276170B2 (enExample) |
| ES (1) | ES2971096T3 (enExample) |
| MX (2) | MX393691B (enExample) |
| TW (1) | TWI714596B (enExample) |
| WO (1) | WO2016200688A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2971096T3 (es) * | 2015-06-06 | 2024-06-03 | Cloudbreak Therapeutics Llc | Composiciones y métodos para tratar el terigio |
| TWI664965B (zh) * | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
| CA3026118A1 (en) | 2016-06-02 | 2017-12-07 | Cloudbreak Therapeutics, Llc | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization |
| US11278546B2 (en) * | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| WO2018054077A1 (en) * | 2016-09-26 | 2018-03-29 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | Composition for treating ocular diseases and methods of usage and making |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| US10335313B2 (en) * | 2017-08-16 | 2019-07-02 | Brian S. Boxer Wachler | Method for removing colored spots to whiten the eye |
| US20200345637A1 (en) * | 2018-01-19 | 2020-11-05 | Aiviva Biopharma, Inc. | Suspension compositions of multi-target inhibitors |
| US20190346048A1 (en) | 2018-05-11 | 2019-11-14 | Quarter Turn Pressure Control, LLC | Replaceable body saver |
| CN112165934A (zh) * | 2018-05-25 | 2021-01-01 | 克劳德布雷克医疗有限责任公司 | 治疗眼充血的组合物及用其治疗眼充血的方法 |
| US10941902B2 (en) | 2018-07-10 | 2021-03-09 | Quarter Turn Pressure Control, LLC | Valve grease blocks for high pressure valves and high pressure valves using the same |
| CA3109703C (en) * | 2018-08-15 | 2023-10-17 | Aiviva Biopharma, Inc. | Multi-kinase inhibitors of vegf and tgf beta and uses thereof |
| WO2020047146A1 (en) * | 2018-08-28 | 2020-03-05 | Cloudbreak Therapeutics, Llc | Emulsion formulations of multikinase inhibitors |
| US10744153B1 (en) * | 2019-07-01 | 2020-08-18 | Cloudbreak Therapeutics Llc | Compositions and methods for treating meibomian gland dysfunction |
| JP2022547401A (ja) * | 2019-09-10 | 2022-11-14 | クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー | 翼状片に関連した眼の見た目についての心配を軽減するための方法 |
| US20240216370A1 (en) * | 2020-02-19 | 2024-07-04 | Vestlandets Innovasjonsselskap As | Treatment of corneal vascularisation |
| PT3884929T (pt) | 2020-03-25 | 2023-08-09 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor da tirosina cinase |
| EP4157238A4 (en) * | 2020-06-01 | 2024-07-24 | ADS Therapeutics LLC | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS AND METHODS FOR TREATING ABNORMAL ANGIOGENESIS |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
| CN113425728A (zh) * | 2021-06-29 | 2021-09-24 | 复旦大学附属眼耳鼻喉科医院 | 一种zd6474在翼状胬肉术后抗复发的治疗药物制备中的应用 |
| WO2024037982A1 (en) * | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
| WO2024124411A1 (zh) * | 2022-12-13 | 2024-06-20 | 苏州锐明新药研发有限公司 | 萘脲类化合物在制备治疗翼状胬肉的药物中的应用 |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
| USD1122994S1 (en) * | 2023-11-30 | 2026-04-21 | J. C. Bamford Excavators Limited | Part of an excavator arm |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739271B2 (en) * | 1997-02-14 | 2001-10-11 | Kissei Pharmaceutical Co. Ltd. | Agents inhibiting progress of pterygium and postoperative recurrence of the same |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| WO2006004795A2 (en) * | 2004-06-25 | 2006-01-12 | The Johns Hopkins University | Angiogenesis inhibitors |
| WO2006020979A2 (en) | 2004-08-13 | 2006-02-23 | Yale University | Factor vii conjugates for selectively treating neovascularization disorders |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2007038453A2 (en) * | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
| US20080003219A1 (en) * | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
| US8558002B2 (en) * | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| EP4249063A3 (en) | 2007-04-05 | 2024-03-13 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| RU2351298C1 (ru) * | 2007-11-27 | 2009-04-10 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ профилактики рецидива птеригиума |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| EP2299987B1 (en) | 2008-06-06 | 2018-02-21 | Boehringer Ingelheim International GmbH | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| US20100185564A1 (en) | 2009-01-21 | 2010-07-22 | Mccormick & Company, Inc. | Method and questionnaire for measuring consumer emotions associated with products |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| US8647659B2 (en) * | 2010-01-22 | 2014-02-11 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| CN102018686B (zh) * | 2010-12-16 | 2012-12-05 | 浙江大学医学院附属邵逸夫医院 | 含有丝裂霉素的膜剂及其制备方法 |
| PH12013502489B1 (en) | 2011-06-03 | 2019-04-24 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| JP5998213B2 (ja) * | 2011-06-28 | 2016-09-28 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | レゴラフェニブを含有する眼科用局所医薬組成物 |
| CA2840491A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sorafenib |
| ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
| DK3181122T3 (da) | 2012-01-13 | 2023-06-06 | Xspray Pharma Ab Publ | Farmaceutisk dasatinib-sammensætning |
| CN103212075B (zh) * | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| US20150037422A1 (en) | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| CN111700880A (zh) | 2012-05-03 | 2020-09-25 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
| HK1204992A1 (en) * | 2012-06-25 | 2015-12-11 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sunitinib |
| CA2877715A1 (en) | 2012-06-25 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing axitinib |
| JP2015520231A (ja) * | 2012-06-25 | 2015-07-16 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ | セジラニブを含んでいる眼科用局所医薬組成物 |
| CA2877710A1 (en) | 2012-06-25 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing pazopanib |
| EP2906145A4 (en) | 2012-10-11 | 2016-07-06 | Univ Colorado Regents | OKULAR FILTER DEVICES, SYSTEMS AND METHOD |
| KR102467714B1 (ko) * | 2012-11-08 | 2022-11-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
| WO2014078655A1 (en) | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| US8747852B1 (en) | 2012-12-28 | 2014-06-10 | Randal Tanh Hoang Pham | Methods of treating pterygium |
| US20160038760A1 (en) * | 2013-03-14 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Conjunctival diseases |
| ES2834964T3 (es) * | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| AU2014259694B2 (en) * | 2013-05-03 | 2018-11-08 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
| US20140378401A1 (en) | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
| CA2936239A1 (en) | 2014-01-16 | 2015-07-23 | Ontogenesis, Llc | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| CN104448300B (zh) * | 2014-12-09 | 2017-01-11 | 西安医学院 | 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用 |
| WO2016123151A1 (en) | 2015-01-26 | 2016-08-04 | University Of Washington | Bumped kinase inhibitor compositions and methods for treating cancer |
| ES2971096T3 (es) * | 2015-06-06 | 2024-06-03 | Cloudbreak Therapeutics Llc | Composiciones y métodos para tratar el terigio |
| CR20170566A (es) | 2015-06-09 | 2018-03-20 | Bayer Pharma AG | Moduladores alostéricos positivos del receptor muscarínico m2 |
| TWI664965B (zh) | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
| AU2016297642A1 (en) | 2015-07-22 | 2018-02-15 | Incept, Llc | Coated punctal plug |
| CA3010623A1 (en) | 2016-02-04 | 2017-08-10 | Jinsong Ni | Antibody-drug synergism technology for treating diseases |
| CA3026118A1 (en) | 2016-06-02 | 2017-12-07 | Cloudbreak Therapeutics, Llc | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization |
| US11278546B2 (en) | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| WO2018054077A1 (en) | 2016-09-26 | 2018-03-29 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | Composition for treating ocular diseases and methods of usage and making |
| MX2019003623A (es) | 2016-09-28 | 2019-09-23 | Medicon Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de afecciones oftalmicas. |
| CN116063221A (zh) | 2017-03-14 | 2023-05-05 | 新源生物科技股份有限公司 | 尼达尼布的晶型 |
| CN112165934A (zh) | 2018-05-25 | 2021-01-01 | 克劳德布雷克医疗有限责任公司 | 治疗眼充血的组合物及用其治疗眼充血的方法 |
| CN110664757B (zh) | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
| JP2022547401A (ja) | 2019-09-10 | 2022-11-14 | クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー | 翼状片に関連した眼の見た目についての心配を軽減するための方法 |
| CN115697333A (zh) | 2020-02-19 | 2023-02-03 | 科尼尔赛德生物医学公司 | 包含阿西替尼的组合物和治疗眼部疾病的方法 |
| CN116251186B (zh) | 2021-12-09 | 2025-04-25 | 成都瑞沐生物医药科技有限公司 | 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途 |
-
2016
- 2016-06-03 ES ES16808064T patent/ES2971096T3/es active Active
- 2016-06-03 KR KR1020267004435A patent/KR20260025887A/ko active Pending
- 2016-06-03 WO PCT/US2016/035726 patent/WO2016200688A1/en not_active Ceased
- 2016-06-03 JP JP2018515193A patent/JP6868014B2/ja active Active
- 2016-06-03 EP EP16808064.6A patent/EP3302379B1/en active Active
- 2016-06-03 KR KR1020267008744A patent/KR20260046518A/ko active Pending
- 2016-06-03 CN CN201680042858.1A patent/CN108135737B/zh active Active
- 2016-06-03 KR KR1020247006976A patent/KR20240034866A/ko not_active Ceased
- 2016-06-03 KR KR1020187000359A patent/KR102643821B1/ko active Active
- 2016-06-03 MX MX2017015838A patent/MX393691B/es unknown
- 2016-06-03 KR KR1020247010160A patent/KR102906248B1/ko active Active
- 2016-06-03 AU AU2016276170A patent/AU2016276170B2/en active Active
- 2016-06-03 EP EP23210844.9A patent/EP4335418A3/en active Pending
- 2016-06-03 CN CN202111180633.1A patent/CN114010787A/zh active Pending
- 2016-06-04 TW TW105117765A patent/TWI714596B/zh active
- 2016-12-12 US US15/375,820 patent/US9980901B2/en active Active
-
2017
- 2017-03-30 US US15/474,620 patent/US9987223B2/en active Active
- 2017-12-06 MX MX2022007989A patent/MX2022007989A/es unknown
-
2018
- 2018-05-29 US US15/991,382 patent/US10149819B2/en active Active
- 2018-05-29 US US15/991,698 patent/US10149820B2/en active Active
- 2018-12-05 US US16/210,896 patent/US10980741B2/en active Active
-
2021
- 2021-04-09 JP JP2021066291A patent/JP7234283B2/ja active Active
- 2021-04-12 US US17/227,877 patent/US12186424B2/en active Active
- 2021-08-20 AU AU2021218212A patent/AU2021218212B2/en active Active
-
2023
- 2023-02-21 JP JP2023024878A patent/JP7571171B2/ja active Active
-
2024
- 2024-02-14 AU AU2024200946A patent/AU2024200946B2/en active Active
- 2024-03-08 JP JP2024035547A patent/JP7838007B2/ja active Active
- 2024-12-04 US US18/968,493 patent/US20250262148A1/en active Pending
-
2025
- 2025-03-19 JP JP2025044397A patent/JP7774170B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7838007B2 (ja) | 翼状片を治療するための組成物及び方法 | |
| TWI757367B (zh) | HDM2-p53交互作用抑制劑之劑量及療法 | |
| JP2018521120A5 (enExample) | ||
| JP2022544234A5 (enExample) | ||
| AU2011322597B2 (en) | Dosing regimes for the treatment of ocular vascular disease | |
| JP2025503385A5 (enExample) | ||
| US20250041277A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| CN117957000A (zh) | 药物组合物及其用途 | |
| CN118201615A (zh) | 喹唑啉酮化合物用于治疗癌症的新用途 | |
| TW202110448A (zh) | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 | |
| CN108289850A (zh) | 含有氨氯地平、氯沙坦和氯噻酮的药物复合制剂 | |
| EP4615869A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| JP2014533283A (ja) | ４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤 | |
| US11666563B2 (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| AU2011339150B2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| JP2023536944A (ja) | 疾患の治療におけるｂｔｋ阻害剤の使用 | |
| JP2022547401A5 (enExample) | ||
| US20080234285A1 (en) | Combination of Organic Compounds | |
| JP2024517477A5 (enExample) | ||
| US20050176725A1 (en) | Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer | |
| CN109875999B (zh) | 泊那替尼在kit突变型恶性黑色素瘤中的应用 | |
| WO2020101597A2 (en) | Capsule compositions comprising tyrosine-kinase inhibitors | |
| JP7807247B2 (ja) | シェーグレン症候群治療剤 |